| Literature DB >> 28794848 |
Md Towhidul Islam1, Reda M Felfel1,2, Ensanya A Abou Neel3,4,5, David M Grant1, Ifty Ahmed1, Kazi M Zakir Hossain1.
Abstract
An overview of the formation of calcium phosphate under in vitro environment on the surface of a range of bioactive materials (e.g. from silicate, borate, and phosphate glasses, glass-ceramics, bioceramics to metals) based on recent literature is presented in this review. The mechanism of bone-like calcium phosphate (i.e. hydroxyapatite) formation and the test protocols that are either already in use or currently being investigated for the evaluation of the bioactivity of biomaterials are discussed. This review also highlights the effect of chemical composition and surface charge of materials, types of medium (e.g. simulated body fluid, phosphate-buffered saline and cell culture medium) and test parameters on their bioactivity performance. Finally, a brief summary of the biomedical applications of these newly formed calcium phosphate (either in the form of amorphous or apatite) is presented.Entities:
Keywords: In vitro; bioactivity; calcium phosphate; ceramic; glass
Year: 2017 PMID: 28794848 PMCID: PMC5524250 DOI: 10.1177/2041731417719170
Source DB: PubMed Journal: J Tissue Eng ISSN: 2041-7314 Impact factor: 7.813
Figure 1.Compositional diagram representing the bone-bonding properties of bioactive glasses. Adapted with permission from Hench.[76]
Figure 2.Schematic illustration of the reaction mechanism of HCA formation on the surface of silicate based bioglass according to Hench and colleagues.[79, 80] Adapted with permission from Gunawidjaja et al.[81]
Figure 3.Schematic illustration of the mechanisms of conversion of borate (3B: B2O3-46.1, CaO-26.9, Na2O-24.4, P2O5-2.6 in mol%) glass and 45S5 (0B: SiO2-46.1, CaO-26.9, Na2O-24.4, P2O5-2.6 in mol%) glass to HA in a dilute phosphate solution. Adapted with permission from Huang et al.[74]
Figure 4.SEM images showing the reaction products for (a) silicate and (b) borate glasses after immersion in dilute K2HPO4 solution (20 mM). Adapted with permission from Huang et al.[74]
Figure 5.Schematic of ion adsorption on (a) positively charged and (b) negatively charged Ti metal in SBF medium. Adapted with permission from Pattanayak et al.[100]
Parameters and test protocols that have been used to investigate the bioactivity of various biomaterials.
| Materials | Medium | Geometry | Surface area or mass/vol | Condition | Length of study | Comments | Ref |
|---|---|---|---|---|---|---|---|
| Silicate glass (45S5) | SBF | Block (1 × 1.5 × 0.2 cm3) | S/V = 0.05 cm−1 | Static | 14 days | HA formed (2 days) | Helebrant et al.[ |
| Glass-ceramics (A-W) | SBF | Block (22 × 40 × 2 mm[ | 200 mL | – | 30 days | HA formed (7 days) | Kokubo et al.[ |
| Silicate glass (45S5/S53P4/S68) | SBF/TRIS/Na-PBS | Block (20 × 15 × 1.5 mm3) | 20 mL S/V = 0.4 cm−1 | Solution was replenished after 7 days | 14 days | CaP layer formed on 45S5/S53P4 (24 h) and S68 (7 days) | Varila et al.[ |
| Borate glass 15Na2O–15CaO–xB2O3–(70-x)P2O5 | SBF | Particles (106–180 µm) | 500 mg in 50 mL | – | 30 days | HA formation increased with increasing B2O3 content | Abo-Naf et al.[ |
| Silicate glass (37CaO–58SiO2–5P2O5) | SBF | Powder (<20 mm particles) | 600 mg in 1 L | Stirring (100 r/min) | 30 days | HCA formed (24 h) | Turdean-Ionescu et al.[ |
| Silicate glass (46S6) | SBF | Disc (13 mm diameter × 5 mm thick) | 30 mL | Agitation | 30 days | HA formed (1 day) | Bui et al.[ |
| Bioceramics (A-W; BG; HA; HA/TCP; α-TCP; β-TCP) | SBF | Cube (5 × 5 × 5 mm3) | 200 mL | – | – | OCP formed (1 day) on all bioceramics except on β -TCP | Xin et al.[ |
| Calcium aluminate (CA), glass ionomer cement (GIC), CA/GIC hybrid | PBS | Block (22 × 15 × 4 mm3) | 50 mL | PBS was changed once a week | 28 days | HA formed on CA (24 h) and CA/GIC hybrid (7 days) | Lööf et al.[ |
| Silicate glass 41.7SiO2-(44.14-X) CaO-XMgO-3.13ZnO-5.2Na2O-K2O-4.7P2O5 | SBF and Tris-buffer | Powder (<45 μm) | 75 mg in 50 mL | Agitated using mechanical shaker | 30 days | HA formed on non-magnesium containing glasses by 7 days in both SBF and Tris-buffer whereas HA formed on Mg containing glasses after 1 month in SBF but not in Tris-buffer | Al-Noaman et al.[ |
| Bioceramics (HA) | SBF | Particles (<5 mm) | 50 mg in 120 mL | – | 120 h | HA formed (12 h) | Kim et al.[ |
| Glass-ceramics (A-W) | SBF | Block (22 × 40 × 2 mm3) | 200 mL | – | 60 days | HA formed (7 days) | Kokubo et al.[ |
| Glass-ceramic (Ceravital) | SBF | Block (15 × 10 × 1 mm3) | 35 mL | – | 20 days | HCA formed (1 day) | Ohtsuki et al.[ |
| Borate glass (45B5) | K2HPO4 (0.25 M) | Disc (15-mm diameter and 3-mm thick) | – | – | 14 days | HA formed (1 day) | Liang et al.[ |
| Borate glass (36–61 mol% B2O3) | SBF/K2HPO4 (0.25 M) | Powder (25−75 μm) | 1.5 mg/mL ratio | Gentle agitation | 7 days | HCA formed (6 h) | Lepry and Nazhat[ |
| Borate glass | K2HPO4 (0.2 M) | Disc (5-mm diameter × 5-mm thick) | 100 mL | Static | 7 days | HA formed (6 days) | Liang et al.[ |
| Silicate glass (58S) | DMEM | Particles (20–40 µm) | 75 mg in 50 mL | Solution was changed at 6 h, 24 h, and 2 days | 3 days | HCA formed (3 days) | Theodorou et al.[ |
| Titanium alloy (Ti6Al4V) | DMEM | Block (10 × 10 × 1 mm3) | 40 mL | – | 360 h | HA formed (360 h) | Faure et al.[ |
| ISO/23317:2014(E) | SBF | Disc (10-mm diameter × 2-mm thick). | Vs = Sa/10 mL ratio | Static | 30 days | Apatite formation | ISO 23317:2014[ |
| Unified method (TC04) | SBF | Particles (45–90 µm) | 75 mg in 50 mL | Agitation (120 r/min) | 28 days | Apatite formation | Maçon et al.[ |
SBF: simulated body fluid; HA: hydroxyapatite; PBS: phosphate-buffered saline; CaP: calcium phosphate; HCA: hydroxycarbonate apatite; DMEM: Dulbecco’s Modified Eagle’s Medium; OCP: octacalcium phosphate; TCP: tricalcium phosphate.
Ionic concentration in human blood plasma in comparison with various developed SBF medium.[145]
| Ion | Human blood plasma (pH 7.2–7.4) | Ion concentration (10−3 mol) in | ||
|---|---|---|---|---|
| SBF (pH 7.4) | Revised-SBF (r-SBF) | Modified-SBF (m-SBF) | ||
| Na+ | 142.0 | 142.0 | 142.0 | 142.0 |
| K+ | 5.0 | 5.0 | 5.0 | 5.0 |
| Mg2+ | 1.5 | 1.5 | 1.5 | 1.5 |
| Ca2+ | 2.5 | 2.5 | 2.5 | 2.5 |
| Cl− | 103.0 | 147.8 | 103.0 | 103.0 |
|
| 27.0 | 4.2 | 27.0 | 10 |
|
| 1.0 | 1.0 | 1.0 | 1.0 |
|
| 0.5 | 0.5 | 0.5 | 0.5 |
SBF: simulated body fluid.
Figure 6.Examples of biomedical applications of CaP based materials (e.g. β-tricalcium phosphate, dicalcium phosphate, dicalcium phosphate dehydrate, tricalcium phosphate and calcium apatite) used in form of coating for hip prostheses and dental screws, porous bone graft, bone cements and pastes. Adapted with permission from Dorozhkin et al.[159]
Figure 7.Examples of additive manufactured implants based on CaP; (a) 3D scaffolds of DCPA/monetite (scale bar: 5 mm), Adapted with permission from Butscher et al.[162] (b) implant made of DCPA for treatment of cranial bone defects (Craniomosaic). DCPA is dicalcium phosphate. Adapted with permission from Habraken et al.[161]
Figure 8.CaP nanoparticles for drug and gene delivery applications; (a) CaP nanorods paste containing DNA encoding fro BMP-7 and VEGF-A for repairing bone defect, Adapted with permission from Chernousova et al.[166] (b) multi-shell design of CaP nanoparticles loaded with antigen and TLR ligand. Adapted with permission from Sokolova et al.[167]